Valneva (VALN) said Monday the Brazilian Health Regulatory Agency has granted marketing authorization for its single-dose vaccine, IXCHIQ, for individuals 18 years and above to prevent disease caused by the chikungunya virus.
The decision marks the world's first approval of a chikungunya vaccine in an endemic country, the company said.
The approval allows for starting of large-scale clinical trials of the vaccine in Brazil, including phase 4 studies that support approval by the US Food and Drug Administration and the European Commission to generate additional data, it said.
Shares of Valneva were up over 7% in recent trading.
Price: 6.74, Change: +0.45, Percent Change: +7.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.